Giuseppe
Emeritus
Evidence of intense ongoing endemic transmission of hepatitis C virus in Egypt (Proc Natl Acad Sci USA, abstract, edited)
[Source: PNAS, full text and links, <cite cite="http://www.pnas.org/content/107/33/14757.short?rss=1">Evidence of intense ongoing endemic transmission of hepatitis C virus in Egypt ? PNAS</cite>. Abstract, edited.]
Evidence of intense ongoing endemic transmission of hepatitis C virus in Egypt
F. DeWolfe Miller (a) and Laith J. Abu-Raddad (b,c,d)
Author Affiliations
(a) Department of Tropical Medicine, Medical Microbiology and Pharmacology, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI 96813;
(b) Infectious Disease Epidemiology Group, Weill Cornell Medical College?Qatar, Cornell University, Qatar Foundation?Education City, Doha, Qatar;
(c) Department of Public Health, Weill Cornell Medical College, Cornell University, New York, NY 10065; and
(d) Vaccine and Infectious Disease Institute, Fred Hutchinson Cancer Research Center, Seattle, WA 98109
Communicated by Kirk R. Smith, University of California, Berkeley, CA, June 22, 2010 (received for review December 24, 2009)
Abstract
Egypt has the highest prevalence of antibodies to hepatitis C virus (HCV) in the world, estimated nationally at 14.7%. An estimated 9.8% are chronically infected. Numerous HCV prevalence studies in Egypt have published various estimates from different Egyptian communities, suggesting that Egypt, relative to the other nations of the world, might be experiencing intense ongoing HCV transmission. More importantly, a new national study provided an opportunity to apply established epidemiologic models to estimate incidence. Validated mathematical models for estimating incidence from age-specific prevalence were used. All previous prevalence studies of HCV in Egypt were reviewed and used to estimate incidence provided that there was sufficient age-specific data required by the models. All reports of anti-HCV antibody prevalence were much higher than any single other national estimate. Age was the strongest and most consistently associated factor to HCV prevalence and HCV RNA positivity. It was not possible to establish a prior reference point for HCV prevalence or incidence to compare with the 2009 incidence estimates. The modeled incidence from the national study and collectively from the modeled incidence from the previous community studies was 6.9/1,000 [95% confidence interval (CI), 5.5?7.4] per person per year and 6.6/1,000 (95% CI, 5.1?7.0) per person per year, respectively. Projected to the age structure of the Egyptian population, more than 500,000 new HCV infections per year were estimated. Iatrogenic transmission is the most likely, underlining exposure to the ongoing transmission. The study demonstrates the urgency to reduce HCV transmission in Egypt.
* incidence
* iatrogentic transmission
* parenteral transmission
* Middle East and North Africa
* mathematical modeling
Footnotes
To whom correspondence should be addressed. E-mail: dewolfe@hawaii.edu.
Author contributions: F.D.M. designed research; F.D.M. and L.J.A-R. performed research; F.D.M. contributed new reagents/analytic tools; F.D.M. and L.J.A-R. analyzed data; and F.D.M. and L.J.A-R. wrote the paper.
The authors declare no conflict of interest.
Freely available online through the PNAS open access option.
-
-----
[Source: PNAS, full text and links, <cite cite="http://www.pnas.org/content/107/33/14757.short?rss=1">Evidence of intense ongoing endemic transmission of hepatitis C virus in Egypt ? PNAS</cite>. Abstract, edited.]
Evidence of intense ongoing endemic transmission of hepatitis C virus in Egypt
F. DeWolfe Miller (a) and Laith J. Abu-Raddad (b,c,d)
Author Affiliations
(a) Department of Tropical Medicine, Medical Microbiology and Pharmacology, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI 96813;
(b) Infectious Disease Epidemiology Group, Weill Cornell Medical College?Qatar, Cornell University, Qatar Foundation?Education City, Doha, Qatar;
(c) Department of Public Health, Weill Cornell Medical College, Cornell University, New York, NY 10065; and
(d) Vaccine and Infectious Disease Institute, Fred Hutchinson Cancer Research Center, Seattle, WA 98109
Communicated by Kirk R. Smith, University of California, Berkeley, CA, June 22, 2010 (received for review December 24, 2009)
Abstract
Egypt has the highest prevalence of antibodies to hepatitis C virus (HCV) in the world, estimated nationally at 14.7%. An estimated 9.8% are chronically infected. Numerous HCV prevalence studies in Egypt have published various estimates from different Egyptian communities, suggesting that Egypt, relative to the other nations of the world, might be experiencing intense ongoing HCV transmission. More importantly, a new national study provided an opportunity to apply established epidemiologic models to estimate incidence. Validated mathematical models for estimating incidence from age-specific prevalence were used. All previous prevalence studies of HCV in Egypt were reviewed and used to estimate incidence provided that there was sufficient age-specific data required by the models. All reports of anti-HCV antibody prevalence were much higher than any single other national estimate. Age was the strongest and most consistently associated factor to HCV prevalence and HCV RNA positivity. It was not possible to establish a prior reference point for HCV prevalence or incidence to compare with the 2009 incidence estimates. The modeled incidence from the national study and collectively from the modeled incidence from the previous community studies was 6.9/1,000 [95% confidence interval (CI), 5.5?7.4] per person per year and 6.6/1,000 (95% CI, 5.1?7.0) per person per year, respectively. Projected to the age structure of the Egyptian population, more than 500,000 new HCV infections per year were estimated. Iatrogenic transmission is the most likely, underlining exposure to the ongoing transmission. The study demonstrates the urgency to reduce HCV transmission in Egypt.
* incidence
* iatrogentic transmission
* parenteral transmission
* Middle East and North Africa
* mathematical modeling
Footnotes
To whom correspondence should be addressed. E-mail: dewolfe@hawaii.edu.
Author contributions: F.D.M. designed research; F.D.M. and L.J.A-R. performed research; F.D.M. contributed new reagents/analytic tools; F.D.M. and L.J.A-R. analyzed data; and F.D.M. and L.J.A-R. wrote the paper.
The authors declare no conflict of interest.
Freely available online through the PNAS open access option.
-
-----